image
Healthcare - Medical - Devices - NASDAQ - US
$ 3.44
-1.76 %
$ 436 M
Market Cap
-37.11
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CTKB stock under the worst case scenario is HIDDEN Compared to the current market price of 3.44 USD, Cytek Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CTKB stock under the base case scenario is HIDDEN Compared to the current market price of 3.44 USD, Cytek Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CTKB stock under the best case scenario is HIDDEN Compared to the current market price of 3.44 USD, Cytek Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CTKB

image
$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
200 M REVENUE
3.85%
-20.5 M OPERATING INCOME
26.30%
-6.02 M NET INCOME
50.44%
25.4 M OPERATING CASH FLOW
380.57%
-83 M INVESTING CASH FLOW
11.63%
-15.8 M FINANCING CASH FLOW
62.16%
41.5 M REVENUE
-27.87%
-15 M OPERATING INCOME
-501.51%
-11.4 M NET INCOME
-118.24%
-125 K OPERATING CASH FLOW
-6.26%
9.45 M INVESTING CASH FLOW
114.90%
-11.5 M FINANCING CASH FLOW
-217.17%
Balance Sheet Cytek Biosciences, Inc.
image
Current Assets 396 M
Cash & Short-Term Investments 278 M
Receivables 60.6 M
Other Current Assets 58 M
Non-Current Assets 103 M
Long-Term Investments 0
PP&E 28.1 M
Other Non-Current Assets 74.9 M
55.63 %12.13 %11.61 %5.63 %15.00 %Total Assets$499.5m
Current Liabilities 67.7 M
Accounts Payable 5.53 M
Short-Term Debt 8.41 M
Other Current Liabilities 53.7 M
Non-Current Liabilities 36.1 M
Long-Term Debt 8.6 M
Other Non-Current Liabilities 27.5 M
5.33 %8.11 %51.77 %8.29 %26.50 %Total Liabilities$103.8m
EFFICIENCY
Earnings Waterfall Cytek Biosciences, Inc.
image
Revenue 200 M
Cost Of Revenue 89.3 M
Gross Profit 111 M
Operating Expenses 132 M
Operating Income -20.5 M
Other Expenses -14.5 M
Net Income -6.02 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)200m(89m)111m(132m)(21m)15m(6m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.43% GROSS MARGIN
55.43%
-10.24% OPERATING MARGIN
-10.24%
-3.00% NET MARGIN
-3.00%
-1.52% ROE
-1.52%
-1.21% ROA
-1.21%
-4.92% ROIC
-4.92%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cytek Biosciences, Inc.
image
25m25m20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)202020202021202120222022202320232024202420252025
Net Income -6.02 M
Depreciation & Amortization 10.5 M
Capital Expenditures -3.52 M
Stock-Based Compensation 26.8 M
Change in Working Capital 0
Others -10.8 M
Free Cash Flow 21.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cytek Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for CTKB of $9 , with forecasts ranging from a low of $5.25 to a high of $16 .
CTKB Lowest Price Target Wall Street Target
5.25 USD 52.62%
CTKB Average Price Target Wall Street Target
9 USD 161.63%
CTKB Highest Price Target Wall Street Target
16 USD 365.12%
Price
Max Price Target
Min Price Target
Average Price Target
161614141212101088664422Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Cytek Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
97.3 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer Cytek has announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. globenewswire.com - 2 weeks ago
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL. globenewswire.com - 2 weeks ago
Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Chad Wiatrowski - TD Cowen Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences First Quarter 2025 Earnings Conference Call. seekingalpha.com - 1 month ago
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago. zacks.com - 1 month ago
Cytek Biosciences Reports First Quarter 2025 Financial Results FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. globenewswire.com - 1 month ago
Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued? The relative valuations conducted in this article suggest that Cytek presents an undervaluation in the range of 16.43% to 109.37%. Cytek has reported net losses due to its growth strategy. In fact, in 2024, its operating expenses represented 65.67% of its sales. In 2024, the company reported cash and cash equivalents and marketable securities of $277.86 million. Meanwhile, its total liabilities were $103.76 million in that year. seekingalpha.com - 1 month ago
Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025 Cytek Biosciences is showcasing its patented Full Spectrum Profiling™ technology at CYTO 2025 & American Association of Immunologists' (AAI) IMMUNOLOGY2025 globenewswire.com - 1 month ago
Why Cytek Biosciences Should Beat Q1 Earnings Expectations There are still growth drivers that may positively play out in future quarters, so I'm still optimistic on Cytek Biosciences. Cytek's FY2024 adjusted EBITDA surged 77% YoY, indicating robust profitability potential, supported by effective cost management and a solid balance sheet. Despite a 41% YTD stock decline, Cytek's innovative FSP tech and growing Cytek Cloud user base signal strong future growth prospects. seekingalpha.com - 1 month ago
Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025 FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. globenewswire.com - 1 month ago
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek® Guava® Muse® cell analyzer, creating a next-generation instrument called the Cytek® Muse® Micro. globenewswire.com - 2 months ago
Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Matthew Sykes - Goldman Sachs Chad Wiatrowski - TD Cowen Harrison Parsons - Stephens Inc. Operator Thank you for standing by, and good day, everyone. My name is RG, and I will be your conference operator today. seekingalpha.com - 3 months ago
Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago. zacks.com - 3 months ago
8. Profile Summary

Cytek Biosciences, Inc. CTKB

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 436 M
Dividend Yield 0.00%
Description Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Contact 47215 Lakeview Boulevard, Fremont, CA, 94538 https://cytekbio.com
IPO Date July 23, 2021
Employees 663
Officers Ms. Valerie T. Barnett J.D. Chief Legal Officer & Corporate Secretary Dr. Ming Yan Ph.D. Chief Technology Officer & Director Mr. William D. McCombe Chief Financial Officer Mr. Patrik Sebastian Jeanmonod Head of Corporate Development Analytics Dr. Philippe Busque Ph.D. Senior Vice President of Global Sales & Services Dr. Allen B. Poirson Ph.D. Senior Vice President of Business & Corporate Development Dr. Wenbin Jiang Ph.D. President, Chief Executive Officer & Chairman of the Board